Calithera Biosciences, Inc.

71 articles with Calithera Biosciences, Inc.

• Calithera Biosciences Announces Clinical Trial Collaboration to Evaluate IBRANCE® (palbociclib) and talazoparib in Combination with CB-839

  10/5/2018

  Phase 1/2 trials expected to initiate 1Q2019

• Harpoon Therapeutics Announces Appointments to Board of Directors and Management Team

  9/18/2018

  ​Jonathan Drachman, M.D., former CMO of Seattle Genetics, Brings Immuno-Oncology Expertise to Board.

• Updated Results From Calithera Biosciences' Phase I Study of CB-839 in Combination With Paclitaxel in Patients With Triple Negative Breast Cancer to be Presented at the 2017 San Antonio Breast Cancer Symposium

  12/5/2017

  Based on these data, Calithera has opened a Phase 2 trial exploring the treatment combination in both first line and late line metastatic TNBC patients.

• 

  5 Biotechs With a Whopping 80%+ Buy Rating for Brokers

  12/5/2017

  In an overall good year for pharma and biotech sectors, there have been some standouts.

• Calithera Biosciences' Initial Results From Phase II Study of CB-839 in Combination with Opdivo® (nivolumab) to be Presented at the Society for Immunotherapy of Cancer Meeting

  11/7/2017

  CB-839 is an orally bioavailable glutaminase inhibitor currently in Phase 2 trials, and Opdivo® is a PD-1 immune checkpoint inhibitor designed to overcome immune suppression.

• Calithera Biosciences Reports Third Quarter 2017 Financial Results and Recent Highlights

  11/2/2017

  Calithera will webcast clinical update on CB-839 on November 11, 2017.

• Calithera Announces First Patient Treated in Phase I Cohort of INCB01158 Dosed in Combination With Keytruda

  10/19/2017

  The Phase 1 trial is designed to evaluate the safety and recommended Phase 2 dose of INCB01158 as a monotherapy, and in combination with immune checkpoint therapy.

• Calithera Biosciences Announces Appointment Of Sumita Ray As General Counsel

  10/3/2017

• Calithera Biosciences Appoints Blake Wise To Board Of Directors

  9/22/2017

• Calithera Biosciences Reports Second Quarter 2017 Financial Results And Recent Highlights

  8/9/2017

• Calithera Biosciences Initiates A Randomized Phase II Combination Trial Of CB-839 In Patients With Renal Cell Carcinoma

  8/7/2017

• Calithera Biosciences To Report Second Quarter 2017 Financial Results On Tuesday, August 8, 2017

  8/2/2017

• Calithera Biosciences Announces FDA Fast Track Designation Granted To CB-839 For Treatment Of Patients With Renal Cell Carcinoma

  6/7/2017

• Calithera Biosciences Release: CB-1158 (INCB01158) Phase I Solid Tumor Data Presented At The ASCO Annual Meeting

  6/5/2017

• Calithera Biosciences Reports First Quarter 2017 Financial Results And Recent Highlights

  5/10/2017

• Bristol-Myers Squibb And Calithera Biosciences Expand Collaboration Evaluating Opdivo (Nivolumab) In Combination With CB-839 Into Non-Small Cell Lung Cancer And Melanoma

  5/10/2017

• Calithera Biosciences To Report First Quarter 2017 Financial Results On Tuesday, May 9, 2017

  5/3/2017

• Bay Area's Calithera Biosciences Rockets After Getting $53 Million Upfront in Cancer Deal With Incyte

  1/31/2017

• Incyte And Calithera Biosciences Announce Global Collaboration To Develop And Commercialize CB-1158, A First-In-Class, Small Molecule Arginase Inhibitor

  1/30/2017

• Bristol-Myers Squibb And Calithera Biosciences Announce Clinical Collaboration To Evaluate Opdivo (Nivolumab) In Combination With CB-839 In Clear Cell Renal Cell Carcinoma

  12/21/2016